← All sarcoma trials
Recruiting nowPhase 1Ages 18 Years and up

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Sponsor: Jonsson Comprehensive Cancer Center · NCT07118176 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

Anal CarcinomaBladder CarcinomaBreast CarcinomaCervical CarcinomaCholangiocarcinomaColorectal CarcinomaEsophageal CarcinomaGastric CarcinomaHead and Neck CarcinomaHematopoietic and Lymphatic System NeoplasmHepatocellular CarcinomaLung CarcinomaMalignant Adrenal Gland NeoplasmMalignant Brain NeoplasmMalignant Neoplasm of Unknown PrimaryMalignant Solid NeoplasmMalignant Testicular NeoplasmMalignant Uterine NeoplasmNeuroendocrine NeoplasmOvarian CarcinomaPancreatic CarcinomaPenile CarcinomaPleural CarcinomatosisPrimary Peritoneal CarcinomaProstate CarcinomaSalivary Gland CarcinomaSarcomaSkin CarcinomaSolitary Fibrous TumorThymus CarcinomaThyroid Gland CarcinomaThyroid Gland Medullary CarcinomaUrothelial CarcinomaVaginal Carcinoma

What it tests

  • Computed Tomographyprocedure
  • Fludeoxyglucose F-18other
  • Gallium Ga 68 FAPi-46radiation
  • Positron Emission Tomographyprocedure

Where it's running1 site

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California 90095

    Recruiting now
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Patients with the following suspected or diagnosed cancer types:

  * Adrenal cancer
  * Anal cancer
  * Bladder cancer
  * Brain cancer
  * Breast cancer
  * Cancer of unknown primary (CUP)
  * Cervical cancer
  * Cholangiocarcinoma
  * Colorectal cancer
  * Esophageal cancer
  * Gastric cancer
  * Head and neck cancer
  * Hematologic cancer
  * Hepatocellular carcinoma
  * Lung cancer
  * Medullary thyroid cancer
  * Neuroendocrine neoplasias
  * Ovarian cancer
  * Pancreatic cancer
  * Penile cancer
  * Peritoneal cancer
  * Pleural cancer
  * Prostate cancer
  * Sarcoma
  * Salivary gland cancer
  * Solitary fibrous tumor
  * Skin cancer
  * Testicular cancer
  * Thymus cancer
  * Thyroid cancer
  * Urothelial cancer
  * Uterus cancer
  * Vaginal cancer
* Patients are ≥ 18 years old at the time of the radiotracer administration
* Patient can provide written informed consent
* Patient is able to remain still for duration of imaging procedure (up to one hour)

Exclusion Criteria:

* Patient is pregnant or nursing
* Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high-quality data

Updated 2025-08-12 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.